ACAD - Acadia Pharmaceuticals Inc
IEX Last Trade
16.59
0.270 1.627%
Share volume: 907,400
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$16.32
0.27
1.65%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-03 | 2023-02-28 | 2023-05-08 | 2023-08-03 | 2023-11-03 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 612.766 M | 602.491 M | 587.812 M | 655.305 M | 642.769 M | 632.540 M | 748.956 M | 855.103 M | |
| Current Assets | 532.519 M | 521.552 M | 507.937 M | 502.850 M | 492.628 M | 499.170 M | 616.125 M | 675.296 M | |
| Inventories | 6.327 M | 5.844 M | 6.636 M | 6.095 M | 9.199 M | 20.768 M | 35.819 M | 61.936 M | |
| Other Current Assets | 20.952 M | 22.993 M | 21.398 M | 23.632 M | 23.895 M | 37.950 M | 39.091 M | 42.761 M | |
| Short Term Investments | 20.952 M | 22.993 M | 21.398 M | 23.632 M | 23.895 M | 37.950 M | 39.091 M | 42.761 M | |
| Total Receivables | 68.889 M | 56.136 M | 63.080 M | 70.250 M | 84.156 M | 94.532 M | 102.350 M | 100.079 M | |
| Current Cash | 436.351 M | 436.579 M | 416.823 M | 402.873 M | 375.378 M | 345.920 M | 438.865 M | 470.520 M | |
| Total Non-current Assets | 80.247 M | 80.939 M | 79.875 M | 152.455 M | 150.141 M | 133.370 M | 132.831 M | 179.807 M | |
| Property Plant Equipment | 7.016 M | 6.510 M | 6.021 M | 5.595 M | 5.193 M | 4.884 M | 4.612 M | 4.370 M | |
| Other Assets | 10.044 M | 12.035 M | 12.511 M | 17.356 M | 16.227 M | 5.103 M | 5.104 M | 5.183 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 69.583 M | 68.219 M | 66.855 M | 65.490 M | 110.204 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 612.766 M | 602.491 M | 587.812 M | 655.305 M | 642.769 M | 632.540 M | 748.956 M | 855.103 M | |
| Total liabilities | 177.918 M | 176.805 M | 187.399 M | 281.047 M | 246.976 M | 270.366 M | 317.201 M | 391.059 M | |
| Total current liabilities | 117.681 M | 116.570 M | 125.630 M | 224.301 M | 187.942 M | 209.603 M | 254.254 M | 330.597 M | |
| Accounts Payable | 11.854 M | 10.008 M | 12.746 M | 17.422 M | 18.811 M | 12.310 M | 17.543 M | 19.332 M | |
| Other liabilities | 5.544 M | 6.466 M | 9.074 M | 5.305 M | 9.256 M | 12.660 M | 15.147 M | 11.273 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 5.544 M | 6.466 M | 9.074 M | 5.305 M | 9.256 M | 12.660 M | 15.147 M | 11.273 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 434.848 M | 425.686 M | 400.413 M | 374.258 M | 395.793 M | 362.174 M | 431.755 M | 464.044 M | |
| Common stock | 161.654 M | 161.852 M | 161.995 M | 162.263 M | 163.458 M | 164.234 M | 165.321 M | 164.798 M | |
| Retained earnings | -2.301 B | -2.328 B | -2.370 B | -2.413 B | -2.411 B | -2.477 B | -2.431 B | -2.414 B |